US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Neo-Concept International Group Holdings Limited

1.40

-0.2100-13.04%

Post-market: 1.37-0.0300-2.14%19:59 EST

Volume:210.82K

Turnover:363.38K

Market Cap:5.69M

PE:5.14

High:1.92

Open:1.57

Low:1.40

Close:1.61

52wk High:8.15

52wk Low:0.9000

Shares:4.06M

Float Shares:945.20K

Volume Ratio:0.03

T/O Rate:22.30%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.2723

EPS(LYR):0.2648

ROE:16.08%

ROA:6.19%

PB:0.76

PE(LYR):5.29

Loading ...

Overview Company News Filings

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium

3 Apparel Stocks See Sharp Drop In Momentum Rankings This Week

Benzinga_recent_news

Shell third quarter 2025 update note

Zentalis board member Letai frontrunner to lead NCI, STAT reports

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Fusion Antibodies Advances OptiMAL® Platform in NCI Collaboration

Press Release: SHELL PLC SECOND QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS

Nutanix Poised To Capture Market Share With Expanding Cloud Platform And VMware Disruption: Analyst

Benzinga_recent_news

BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Half-year report

Neo-Concept International Group Holdings Ltd. Conducted Annual General Meeting

Neo-Concept International Group Holdings Ltd Files Prospectus to Offer up to 15 Mln Class a Ordinary Shares - SEC Filing

THOMSON REUTERS

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

DMC Global Reports Second Quarter Financial Results

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NCI/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","market":"US","secType":"STK","nameCN":"Neo-Concept International Group Holdings Limited","latestPrice":1.4,"timestamp":1766005200000,"preClose":1.61,"halted":0,"volume":210820,"hourTrading":{"tag":"盘后","latestPrice":1.37,"preClose":1.4,"latestTime":"19:59 EST","volume":2791,"amount":3813.8484,"timestamp":1766019541188},"delay":0,"floatShares":945200,"shares":4064000,"eps":0.272333,"marketStatus":"Not Yet Opened","change":-0.21,"latestTime":"12-17 16:00:00 EST","open":1.57,"high":1.92,"low":1.395,"amount":363380.73628,"amplitude":0.326087,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.272333,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766048400000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1713844800000,"exchange":"NASDAQ","adjPreClose":1.61,"preHourTrading":{"tag":"盘前","latestPrice":1.54,"preClose":1.61,"latestTime":"09:21 EST","volume":2274,"amount":3533.7389226,"timestamp":1765981297296},"postHourTrading":{"tag":"盘后","latestPrice":1.37,"preClose":1.4,"latestTime":"19:59 EST","volume":2791,"amount":3813.8484,"timestamp":1766019541188},"volumeRatio":0.028033},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCI\",,,,,undefined,":{"symbol":"NCI","floatShares":945200,"roa":"6.19%","roe":"16.08%","lyrEps":0.264768,"volumeRatio":0.028033,"shares":4064000,"dividePrice":0,"high":1.92,"amplitude":0.326087,"preClose":1.61,"low":1.395,"week52Low":0.9,"pbRate":"0.76","psRate":"0.20","week52High":8.15,"institutionHeld":0.7857,"latestPrice":1.4,"eps":0.272333,"divideRate":0,"volume":210820,"delay":0,"ttmEps":0.272333,"open":1.57,"prevYearClose":3.3,"prevWeekClose":1.92,"prevMonthClose":1.17,"prevQuarterClose":1.83,"fiveDayClose":1.23,"twentyDayClose":1,"sixtyDayClose":1.95},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-06-16","symbol":"NCI","defaultRemindTime":1750080600000,"type":"split","dateTimestamp":1750046400000,"forFactor":5,"toFactor":1,"ratio":5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NCI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NCI","date":"2025-12-16","current":5.140765,"percent":0.123188,"low":-615.963293,"twenty":6.183289,"median":8.851868,"eighty":21.045553,"high":50.092968,"avg":7.669115,"sd":39.792818,"marketCap":5892826},"quantilePoints":[{"date":"2024-04-26","current":-152.934443,"twenty":-421.533502,"median":-222.424043,"eighty":-152.416021,"marketCap":47955200},{"date":"2024-05-03","current":-75.704037,"twenty":-208.526123,"median":-121.807344,"eighty":-81.702314,"marketCap":23774400},{"date":"2024-05-10","current":-74.39805,"twenty":-152.15681,"median":-81.565326,"eighty":-71.297323,"marketCap":23368000},{"date":"2024-05-17","current":36.631419,"twenty":-133.739762,"median":-74.39805,"eighty":-23.514082,"marketCap":20726400},{"date":"2024-05-24","current":30.19238,"twenty":-105.051475,"median":-71.169081,"eighty":36.421773,"marketCap":17068800},{"date":"2024-05-31","current":25.951993,"twenty":-89.228644,"median":-65.79629,"eighty":35.854613,"marketCap":14650720},{"date":"2024-06-07","current":26.211896,"twenty":-81.702314,"median":25.015338,"eighty":34.642796,"marketCap":14813280},{"date":"2024-06-14","current":29.519581,"twenty":-78.809845,"median":25.103888,"eighty":32.998302,"marketCap":16682720},{"date":"2024-06-21","current":25.962557,"twenty":-75.44284,"median":25.889128,"eighty":31.491027,"marketCap":14685264},{"date":"2024-06-28","current":22.645555,"twenty":-74.134092,"median":25.192438,"eighty":30.05782,"marketCap":12803632},{"date":"2024-07-05","current":22.365126,"twenty":-73.07826,"median":25.015338,"eighty":29.519581,"marketCap":12639040},{"date":"2024-07-12","current":23.313894,"twenty":-71.810291,"median":24.273321,"eighty":28.980357,"marketCap":13183616},{"date":"2024-07-19","current":21.771249,"twenty":-70.527871,"median":24.005484,"eighty":28.783514,"marketCap":12305792},{"date":"2024-07-26","current":19.871565,"twenty":-67.981499,"median":23.548157,"eighty":28.579978,"marketCap":11236980},{"date":"2024-08-02","current":17.380948,"twenty":-63.611082,"median":23.313894,"eighty":28.402846,"marketCap":9828784},{"date":"2024-08-09","current":14.824233,"twenty":14.824233,"median":22.666232,"eighty":28.339976,"marketCap":8393176},{"date":"2024-08-16","current":14.891311,"twenty":14.824233,"median":22.428658,"eighty":26.393551,"marketCap":8432800},{"date":"2024-08-23","current":16.505019,"twenty":14.824233,"median":21.843651,"eighty":26.38192,"marketCap":9347200},{"date":"2024-08-30","current":15.221442,"twenty":14.891311,"median":21.615595,"eighty":26.235018,"marketCap":8617712},{"date":"2024-09-06","current":14.786956,"twenty":14.816778,"median":21.03365,"eighty":26.21652,"marketCap":8375904},{"date":"2024-09-13","current":18.291286,"twenty":14.783803,"median":19.997266,"eighty":26.012425,"marketCap":10355072},{"date":"2024-09-20","current":25.287335,"twenty":14.816778,"median":19.871565,"eighty":26.012425,"marketCap":14325600},{"date":"2024-09-27","current":18.961375,"twenty":14.877895,"median":19.084343,"eighty":25.954106,"marketCap":10769600},{"date":"2024-10-04","current":21.913118,"twenty":15.042266,"median":20.067523,"eighty":26.126798,"marketCap":12454128},{"date":"2024-10-11","current":22.176748,"twenty":15.165199,"median":20.049509,"eighty":25.99115,"marketCap":12598400},{"date":"2024-10-18","current":32.898839,"twenty":15.206634,"median":20.803771,"eighty":26.126798,"marketCap":18694400},{"date":"2024-10-25","current":23.358148,"twenty":15.219487,"median":21.352319,"eighty":26.21652,"marketCap":13270992},{"date":"2024-11-01","current":27.487373,"twenty":15.232907,"median":21.771249,"eighty":26.583872,"marketCap":15603728},{"date":"2024-11-08","current":26.826792,"twenty":15.38624,"median":21.882165,"eighty":26.827702,"marketCap":15231872},{"date":"2024-11-15","current":22.217928,"twenty":15.464941,"median":22.207911,"eighty":26.517352,"marketCap":12598400},{"date":"2024-11-22","current":19.532206,"twenty":15.526206,"median":22.192329,"eighty":26.402839,"marketCap":11076432},{"date":"2024-11-29","current":19.712189,"twenty":15.580772,"median":21.882165,"eighty":26.386572,"marketCap":11184128},{"date":"2024-12-06","current":18.691913,"twenty":15.639248,"median":21.771249,"eighty":26.293779,"marketCap":10607040},{"date":"2024-12-13","current":18.611126,"twenty":15.691094,"median":21.352319,"eighty":26.221145,"marketCap":10566400},{"date":"2024-12-20","current":7.102414,"twenty":15.639248,"median":20.803771,"eighty":26.151136,"marketCap":10058400},{"date":"2024-12-27","current":7.471029,"twenty":15.444399,"median":20.742686,"eighty":26.108587,"marketCap":10592816},{"date":"2025-01-03","current":10.196837,"twenty":15.213623,"median":20.067523,"eighty":26.07693,"marketCap":14427200},{"date":"2025-01-10","current":10.034934,"twenty":14.891311,"median":20.043836,"eighty":25.962557,"marketCap":14183360},{"date":"2025-01-17","current":9.907617,"twenty":14.749465,"median":19.895277,"eighty":25.951993,"marketCap":14008608},{"date":"2025-01-24","current":9.563114,"twenty":13.631492,"median":19.697706,"eighty":25.85141,"marketCap":13512800},{"date":"2025-01-31","current":8.48834,"twenty":10.018271,"median":19.532206,"eighty":25.746589,"marketCap":11988800},{"date":"2025-02-07","current":7.730432,"twenty":9.882149,"median":19.361654,"eighty":25.46422,"marketCap":10919968},{"date":"2025-02-14","current":7.130829,"twenty":9.483748,"median":19.090069,"eighty":25.309589,"marketCap":10081768},{"date":"2025-02-21","current":7.314786,"twenty":8.865676,"median":18.969464,"eighty":25.26403,"marketCap":10361168},{"date":"2025-02-28","current":5.889209,"twenty":8.594149,"median":18.858804,"eighty":25.21486,"marketCap":8333232},{"date":"2025-03-07","current":6.028973,"twenty":8.100004,"median":18.691913,"eighty":25.173677,"marketCap":8536432},{"date":"2025-03-14","current":5.598897,"twenty":7.846255,"median":18.496802,"eighty":25.10156,"marketCap":7926832},{"date":"2025-03-21","current":5.968988,"twenty":7.540872,"median":18.291286,"eighty":25.033931,"marketCap":8451088},{"date":"2025-03-28","current":7.03753,"twenty":7.389256,"median":18.105135,"eighty":24.856699,"marketCap":9956800},{"date":"2025-04-04","current":6.201809,"twenty":7.119463,"median":17.654152,"eighty":24.701604,"marketCap":8778240},{"date":"2025-04-11","current":6.159082,"twenty":7.009081,"median":17.557752,"eighty":24.560727,"marketCap":8737600},{"date":"2025-04-17","current":6.305413,"twenty":6.892251,"median":17.348506,"eighty":24.472151,"marketCap":8938768},{"date":"2025-04-25","current":5.299322,"twenty":6.518915,"median":16.836333,"eighty":24.40328,"marketCap":7518400},{"date":"2025-05-02","current":4.437465,"twenty":6.31653,"median":16.510738,"eighty":24.325687,"marketCap":6301232},{"date":"2025-05-09","current":5.171449,"twenty":6.285391,"median":16.156269,"eighty":24.224718,"marketCap":7317232},{"date":"2025-05-16","current":6.695699,"twenty":6.181855,"median":15.685852,"eighty":24.063819,"marketCap":6908800},{"date":"2025-05-23","current":7.021962,"twenty":6.235146,"median":15.538955,"eighty":24.008491,"marketCap":7233920},{"date":"2025-05-30","current":8.164705,"twenty":6.285272,"median":15.423857,"eighty":24.005032,"marketCap":8397532},{"date":"2025-06-06","current":8.847265,"twenty":6.289683,"median":15.216555,"eighty":23.931629,"marketCap":9092468},{"date":"2025-06-13","current":8.179292,"twenty":6.306628,"median":15.080005,"eighty":23.644242,"marketCap":8402196},{"date":"2025-06-20","current":10.670242,"twenty":6.311489,"median":14.824233,"eighty":23.64022,"marketCap":10960400},{"date":"2025-06-27","current":11.716334,"twenty":6.315883,"median":14.760327,"eighty":23.456094,"marketCap":12034985},{"date":"2025-07-03","current":10.216346,"twenty":6.317177,"median":14.71349,"eighty":23.384943,"marketCap":10494000},{"date":"2025-07-11","current":10.261711,"twenty":6.410478,"median":11.716334,"eighty":23.359949,"marketCap":10540640},{"date":"2025-07-18","current":9.808428,"twenty":6.454657,"median":10.875077,"eighty":23.322745,"marketCap":10077038},{"date":"2025-07-25","current":9.671429,"twenty":6.462794,"median":10.624987,"eighty":23.130117,"marketCap":9934320},{"date":"2025-08-01","current":8.89955,"twenty":6.57431,"median":10.442049,"eighty":23.054884,"marketCap":9141440},{"date":"2025-08-08","current":8.26371,"twenty":6.676961,"median":10.261711,"eighty":22.850835,"marketCap":8488480},{"date":"2025-08-15","current":8.020396,"twenty":6.711807,"median":10.206559,"eighty":22.709857,"marketCap":8255280},{"date":"2025-08-22","current":7.944228,"twenty":6.718226,"median":10.054926,"eighty":22.653826,"marketCap":8198379},{"date":"2025-08-29","current":7.484931,"twenty":6.73937,"median":9.97069,"eighty":22.584141,"marketCap":7742240},{"date":"2025-09-05","current":9.159836,"twenty":6.821347,"median":9.934593,"eighty":22.562922,"marketCap":9467920},{"date":"2025-09-12","current":9.23611,"twenty":6.883125,"median":9.907617,"eighty":22.500907,"marketCap":9561200},{"date":"2025-09-19","current":8.862273,"twenty":6.893296,"median":9.771265,"eighty":22.442063,"marketCap":9188080},{"date":"2025-09-26","current":7.431141,"twenty":6.901678,"median":9.711704,"eighty":22.390539,"marketCap":7701314},{"date":"2025-10-03","current":7.413811,"twenty":6.942194,"median":9.659792,"eighty":22.276807,"marketCap":7680994},{"date":"2025-10-10","current":7.489961,"twenty":6.99974,"median":9.578721,"eighty":22.211918,"marketCap":7762274},{"date":"2025-10-17","current":7.128574,"twenty":6.974212,"median":9.51173,"eighty":22.189213,"marketCap":7396512},{"date":"2025-10-24","current":6.854291,"twenty":6.883125,"median":9.462569,"eighty":22.01857,"marketCap":7112031},{"date":"2025-10-31","current":6.186973,"twenty":6.854004,"median":9.33225,"eighty":21.875975,"marketCap":6421148},{"date":"2025-11-07","current":4.741629,"twenty":6.765339,"median":9.223624,"eighty":21.842138,"marketCap":4917461},{"date":"2025-11-14","current":4.19042,"twenty":6.696493,"median":9.126243,"eighty":21.797185,"marketCap":4348499},{"date":"2025-11-21","current":3.92273,"twenty":6.462068,"median":9.081059,"eighty":21.677857,"marketCap":4064018},{"date":"2025-11-28","current":4.258196,"twenty":6.343606,"median":9.054357,"eighty":21.613946,"marketCap":4754901},{"date":"2025-12-05","current":4.259674,"twenty":6.293615,"median":8.88422,"eighty":21.40415,"marketCap":4754901},{"date":"2025-12-12","current":4.514242,"twenty":6.192907,"median":8.860854,"eighty":21.069359,"marketCap":5039382},{"date":"2025-12-16","current":5.277042,"twenty":6.183289,"median":8.851868,"eighty":21.045553,"marketCap":5892826}],"updateTime":1766018379797},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCI\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2575543280","title":"PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2575543280","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575543280?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:01","pubTimestamp":1760385660,"startTime":"0","endTime":"0","summary":"Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harbor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165785/0/en/PMV-Pharmaceuticals-to-Present-Rezatapopt-Pivotal-Phase-2-Initial-Analysis-and-Natural-History-Study-Results-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Target.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","01336","BK4139","LU0572939691.SGD","BK1184","BK1550","LU0264606111.USD","BK4539","LU0572940350.SGD","PMVP","NCI","LENZ","BK4202","BK1584"],"gpt_icon":0},{"id":"2575028051","title":"Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575028051","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575028051?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:00","pubTimestamp":1760385600,"startTime":"0","endTime":"0","summary":"Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165776/0/en/Zymeworks-to-Present-Clinical-Data-from-the-Phase-1-trial-of-ZW191-an-Antibody-Drug-Conjugate-Targeting-Folate-Receptor-at-AACR-NCI-EORTC-International-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ET","BK4080","BK1550","01336","BK4590","LU0572940350.SGD","NCI","BK4588","BK4231","LU0572939691.SGD","BK1584","BK4144","LU0264606111.USD","BK1184","BK4202","BK4585","BK4561","BK4581","ADC"],"gpt_icon":0},{"id":"2575228307","title":"Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2575228307","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575228307?lang=en_us&edition=fundamental","pubTime":"2025-10-14 00:00","pubTimestamp":1760371200,"startTime":"0","endTime":"0","summary":"- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET - Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00 p.m. ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165684/37568/en/Merus-Announces-Petosemtamab-in-Metastatic-Colorectal-Cancer-Abstract-Selected-for-Plenary-Session-Oral-Presentation-at-the-AACR-NCI-EORTC-International-Conference-on-Molecular-Tar.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1584","BK4539","LU0572940350.SGD","BK1184","BK4139","NCI","BK4202","LU0572939691.SGD","LU0264606111.USD","BK1550","01336","LENZ","BK4007"],"gpt_icon":0},{"id":"2575074283","title":"Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2575074283","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575074283?lang=en_us&edition=fundamental","pubTime":"2025-10-14 00:00","pubTimestamp":1760371200,"startTime":"0","endTime":"0","summary":"Groundbreaking oncology development with the first dual payload peptide drug conjugate platform, establishing Avacta as a leader in combination therapy innovationLONDON and PHILADELPHIA, Oct.  13, 202","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165666/0/en/Avacta-to-Present-First-Dual-Payload-pre-CISION-Medicines-Data-at-the-2025-EORTC-NCI-AACR-International-Conference-on-Molecular-Targets-Symposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01336","NCI","LU0572940350.SGD","LU0572939691.SGD","MDCO","LU0264606111.USD","BK4202","BK1184","BK1584","BK1550"],"gpt_icon":0},{"id":"2573946823","title":"3 Apparel Stocks See Sharp Drop In Momentum Rankings This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2573946823","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573946823?lang=en_us&edition=fundamental","pubTime":"2025-10-08 16:00","pubTimestamp":1759910400,"startTime":"0","endTime":"0","summary":"3 apparel stocks—Allbirds, Neo-Concept International, and Shoe Carnival—showed sharp momentum declines, dropping in momentum rankings.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/08/Stock-market-chaos.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/08/Stock-market-chaos.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/10/48093619/3-apparel-stocks-see-sharp-drop-in-momentum-rankings-this-week","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/10/48093619/3-apparel-stocks-see-sharp-drop-in-momentum-rankings-this-week","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SDS","ESmain","OEF","BK4534","BK4593","SPXU","PSQ","BK4550","BK4585","QLD","MNQmain","SQQQ","TQQQ","QID","NVIW.SI","IVV","BK4581","SPY","SSO",".SPX","NCI","USAW.SI",".IXIC","BK4146","BK4094","BK4202","BK4561","UPRO","VOO","TSYW.SI","SCVL","NQmain","BK4504","FDN","SH","USJW.SI","MESmain","BK4559","BIRD","OEX","BK4588"],"gpt_icon":1},{"id":"2573934714","title":"Shell third quarter 2025 update note","url":"https://stock-news.laohu8.com/highlight/detail?id=2573934714","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573934714?lang=en_us&edition=fundamental","pubTime":"2025-10-07 14:00","pubTimestamp":1759816800,"startTime":"0","endTime":"0","summary":"The following is an update to the third quarter 2025 outlook and gives an overview of our current expectations for the third quarter. Outlooks presented may vary from the actual third quarter 2025 res","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/07/3162217/0/en/Shell-third-quarter-2025-update-note.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MT","BK4006","BK4561","BK4202","NCI"],"gpt_icon":0},{"id":"2570087623","title":"Zentalis board member Letai frontrunner to lead NCI, STAT reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2570087623","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570087623?lang=en_us&edition=fundamental","pubTime":"2025-09-25 03:40","pubTimestamp":1758742820,"startTime":"0","endTime":"0","summary":"Anthony Letai, a cancer researcher and oncologist at the Dana-Farber Cancer Institute and Harvard University and a member of the scientific advisor...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zentalis-board-member-letai-frontrunner-to-lead-nci-stat-reports-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zentalis-board-member-letai-frontrunner-to-lead-nci-stat-reports-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4202","NCI"],"gpt_icon":0},{"id":"2569789066","title":"Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT","url":"https://stock-news.laohu8.com/highlight/detail?id=2569789066","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569789066?lang=en_us&edition=fundamental","pubTime":"2025-09-22 19:30","pubTimestamp":1758540600,"startTime":"0","endTime":"0","summary":"Non-dilutive payment is part of $17.6 million award granted for the Company’s leptomeningeal cancer targeted radiotherapeutic development program HOUSTON, Sept.  22, 2025  (GLOBE NEWSWIRE) -- Plus The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/22/3153806/0/en/Plus-Therapeutics-Announces-Additional-1-9-Million-Advance-Payment-from-CPRIT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4202","BK4139","NCI","CNS","BK4135","BK4007","LENZ"],"gpt_icon":0},{"id":"2568232457","title":"Fusion Antibodies Advances OptiMAL® Platform in NCI Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2568232457","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568232457?lang=en_us&edition=fundamental","pubTime":"2025-09-17 14:16","pubTimestamp":1758089783,"startTime":"0","endTime":"0","summary":"Fusion Antibodies Plc ( ($GB:FAB) ) has issued an update. Fusion Antibodies plc has announced significant progress in its OptiMAL® project, a colla...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fusion-antibodies-advances-optimal-platform-in-nci-collaboration?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fusion-antibodies-advances-optimal-platform-in-nci-collaboration?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4202","NCI"],"gpt_icon":0},{"id":"2565508867","title":"Press Release: SHELL PLC SECOND QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2565508867","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565508867?lang=en_us&edition=fundamental","pubTime":"2025-09-08 14:00","pubTimestamp":1757311200,"startTime":"0","endTime":"0","summary":"The Board of Shell plc today announced the pounds sterling and euro equivalent dividend payments in respect of the second quarter 2025 interim dividend, which was announced on July 31, 2025 at US$0.358 per ordinary share.Shareholders have been able to elect to receive their dividends in US dollars, euros or pounds sterling. Holders of ordinary shares who have validly submitted US dollars, euros or pounds sterling currency elections by September 1, 2025 will be entitled to a dividend of US$0.358, EUR0.3068 or 26.62p per ordinary share, respectively.Euro and pounds sterling dividends payable in cash have been converted from US dollars based on an average of market exchange rates over the three dealing days from September 3 to September 5, 2025. This dividend will be payable on September 22, 2025 to those members whose names were on the Register of Members on August 15, 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","LU0098860793.USD","LU0278409577.USD","LU2236285917.USD","LU0320765646.SGD","SHEL","BK4202","BK4588","LU0300736492.USD","LU1162221912.USD","BK4585","LU0300736062.USD","BK4201"],"gpt_icon":0},{"id":"2563063524","title":"Nutanix Poised To Capture Market Share With Expanding Cloud Platform And VMware Disruption: Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2563063524","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563063524?lang=en_us&edition=fundamental","pubTime":"2025-08-29 02:58","pubTimestamp":1756407480,"startTime":"0","endTime":"0","summary":"Nutanix ended fiscal 2025 with strong Q4, but near-term contract timing issues clouded investor sentiment. Needham analyst stays positive.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/08/28/Nutanix-Image-by-Piotr-Swat-via-Shutters.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/08/28/Nutanix-Image-by-Piotr-Swat-via-Shutters.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/reiteration/25/08/47397076/nutanix-poised-to-capture-market-share-with-expanding-cloud-platform-and-vmware-disruption-analyst","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/reiteration/25/08/47397076/nutanix-poised-to-capture-market-share-with-expanding-cloud-platform-and-vmware-disruption-analyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["CSCO","VMW","LU1221951046.USD","LU1674673691.USD","LU1894683264.USD","LU2286300806.USD","LU1066053197.SGD","IE00BFXG1179.USD","LU0823417737.USD","LU1267930813.SGD","LU0889566641.SGD","LU1221951129.SGD","IE00B42XCP33.USD","BK4020","SG9999001440.SGD","SG9999015952.SGD","SG9999015978.USD","LU0731783394.SGD","LU0942090050.USD","BK4515","BK4504","IE00BFMHRM44.USD","LU1066051498.USD","LU1196500208.SGD","BK4525","LU0823417653.USD","LU0203347892.USD","LU1599440770.SGD","NCI","LU1883839398.USD","LU0792757196.USD","BK4097","LU2237443465.HKD","SG9999002232.USD","ARR","BK4585","BK4612","LU1880398554.USD","LU2237443978.SGD","LU1571399168.USD","LU2506951875.HKD","LU2506952170.USD","BK4581","IE00BVYPNV92.GBP","IE00B3PB1722.GBP","LU1046421795.USD","LU0348723411.USD","IE00B1BXHZ80.USD","IE00BSNM7G36.USD","LU1430594728.SGD"],"gpt_icon":0},{"id":"2562733893","title":"BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2562733893","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562733893?lang=en_us&edition=fundamental","pubTime":"2025-08-26 19:30","pubTimestamp":1756207800,"startTime":"0","endTime":"0","summary":"Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing potential of BriaCell’s Bria-OTS+ platformBria-OTS+, a novel personalized, off-the-shelf, semi-allogeneic ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/26/3139167/0/en/BriaCell-s-Bria-OTS-Mechanism-of-Action-Validated-in-Highly-Rated-Peer-Reviewed-Cancer-Journal.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX","NCI","BK4139","BK4202"],"gpt_icon":0},{"id":"2560046289","title":"Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2560046289","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560046289?lang=en_us&edition=fundamental","pubTime":"2025-08-18 19:30","pubTimestamp":1755516600,"startTime":"0","endTime":"0","summary":"REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting tox","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/18/3134923/0/en/Plus-Therapeutics-Presents-Positive-ReSPECT-LM-Clinical-Trial-Results-of-REYOBIQ-in-Leptomeningeal-Metastases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","BK4135","CNS","LENZ","BK4539","BK4139","BK4202","BK4007"],"gpt_icon":0},{"id":"2559964326","title":"Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2559964326","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559964326?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:15","pubTimestamp":1755202500,"startTime":"0","endTime":"0","summary":"Announced CNSide CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug.  14, 2025  (GLOBE NEWSWIRE) -- Plus Therapeu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/14/3133893/0/en/Plus-Therapeutics-Reports-Second-Quarter-Financial-Results-and-Recent-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BK4135","LENZ","NCI","BK4139","BK4202","CSF","BK4007","BK4539"],"gpt_icon":0},{"id":"2559793451","title":"Half-year report","url":"https://stock-news.laohu8.com/highlight/detail?id=2559793451","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559793451?lang=en_us&edition=fundamental","pubTime":"2025-08-14 14:00","pubTimestamp":1755151200,"startTime":"0","endTime":"0","summary":"14August 2025 2025 Interim Results Highlights Admiral Group reports excellent H1 2025 results Six months ended:30 June 202530 June 2024% change vs. 2024Group profit before tax from continuing operatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/14/3133176/0/en/Half-year-report.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0980610538.SGD","LU1721429741.USD","LU2089279066.USD","B","D","LU1721429402.USD","LU2413666426.HKD","LU0823414478.USD","LU1244550494.USD","UK","LU1162221912.USD","LU0098860793.USD","SPE","LU2272731865.HKD","LU0323239441.USD","LU0345780521.USD","BK4149","E","ECL","BK4205","IE00B29SXL02.USD","LU2360108059.USD","A","LU2322448957.HKD","LU2322448791.USD","LU2462157665.USD","BK4201","LU2125910336.SGD","IE00BSNM7G36.USD","NAV","LU2272731600.USD","LU0368265764.SGD","LU1923622291.USD","UPL","LU1992135472.HKD","NCI","LU2229751404.USD","BK4566","BK4504","ZEV","IE00BD4GTW91.USD","LU1267930227.SGD","LU0106831901.USD","IE00BMG7P702.HKD","LU0477156953.USD","LU1791807156.HKD","LU2041044095.USD","PD","IE00BMG7P926.USD"],"gpt_icon":1},{"id":"2558647167","title":"Neo-Concept International Group Holdings Ltd. Conducted Annual General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2558647167","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558647167?lang=en_us&edition=fundamental","pubTime":"2025-08-12 21:29","pubTimestamp":1755005373,"startTime":"0","endTime":"0","summary":"Neo-Concept International Group Holdings Ltd. held its Annual General Meeting on August 11, 2025. The meeting included the re-election of Eva Yuk Yin Siu and Man Chi Wai as executive directors, and Josephine Yan Yeung, Mark Gary Singer, and Billy Chun Fai Tang as independent directors. Additionally, WWC, P.C. Certified Public Accountants was re-appointed as the auditor. All proposals were approved by the shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neo-Concept International Group Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 12, 2025, and is solely r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL9DwFpJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","NCI"],"gpt_icon":0},{"id":"2558131693","title":"Neo-Concept International Group Holdings Ltd Files Prospectus to Offer up to 15 Mln Class a Ordinary Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2558131693","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558131693?lang=en_us&edition=fundamental","pubTime":"2025-08-12 05:15","pubTimestamp":1754946913,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250811:nFWN3U3156:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NCI","BK4202"],"gpt_icon":0},{"id":"2557729683","title":"RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire","url":"https://stock-news.laohu8.com/highlight/detail?id=2557729683","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557729683?lang=en_us&edition=fundamental","pubTime":"2025-08-06 20:30","pubTimestamp":1754483400,"startTime":"0","endTime":"0","summary":"RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCath Four active cancer center customers are curre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/06/3128335/0/en/RenovoRx-Expands-U-S-Commercialization-Efforts-for-the-RenovoCath-Device-with-Growing-Customer-Demand-and-Key-Leadership-Hire.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NCI","BK4539","BK4202","RNXT","BK4139"],"gpt_icon":0},{"id":"2557317898","title":"DMC Global Reports Second Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2557317898","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557317898?lang=en_us&edition=fundamental","pubTime":"2025-08-06 04:05","pubTimestamp":1754424300,"startTime":"0","endTime":"0","summary":"Second quarter sales were $155.5 millionNet income attributable to DMC was $0.1 millionAdjusted net income attributable to DMC* was $2.5 million, or $0.12 per diluted shareAdjusted EBITDA attributable","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/05/3127813/0/en/DMC-Global-Reports-Second-Quarter-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","BK4179","BOOM","NCI"],"gpt_icon":0},{"id":"2555806838","title":"Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2555806838","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555806838?lang=en_us&edition=fundamental","pubTime":"2025-07-31 19:30","pubTimestamp":1753961400,"startTime":"0","endTime":"0","summary":"CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private healthcare systems Company will expand testing services and broaden r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/31/3124879/0/en/Plus-Therapeutics-Provides-US-Launch-Update-for-its-CNSide-Diagnostic.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CSF","BK4139","CNS","LENZ","BK4539","NCI","BK4202","BK4135"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":72,"code":"91000000","status":"200"}]}}